The hypothesis that serotonin (S-HT)-stimulated phosphoinositide hydrolysis is mediated by the 5-HT-2 binding site in cerebral cortex was tested by comparing antagonist K, values determined by Schild analyses with Ki values at the 5-HT-2 binding site. A significant correlation was found between Kd values and Ki values at competing for 3H-ketanserin binding (R = 0.98), suggesting that the phosphoinositide-linked receptor and the 5-HT-2 site are identical. The 5-HT-2-mediated phosphoinositide response was then used as a measure of 5-HT-2 receptor sensitivity after in viva treatments that alter the availability of 5-HT. Chronic treatment with the 5-HT-2 antagonist mianserin resulted in a significant decrease (52%) in the density of 5-HT-2 binding sites and a significant decrease (49%) in the maximal phosphoinositide hydrolysis response to 5-HT. Depletion of 5-HT levels with para-chlorophenylalanine or chemical denervation of serotonergic neurons with 5,7-dihydroxytryptamine had no significant effect upon 5-HT-2 receptor density or upon the phosphoinositide response to 5-HT. These data suggest that changes or lack of changes in 5-HT-2 receptor density following in viva manipulations reflect the functional state of the receptor.
The hypothesis that serotonin (S-HT)-stimulated phosphoinositide hydrolysis is mediated by the 5-HT-2 binding site in cerebral cortex was tested by comparing antagonist K, values determined by Schild analyses with Ki values at the 5-HT-2 binding site. A significant correlation was found between Kd values and Ki values at competing for 3H-ketanserin binding (R = 0.98), suggesting that the phosphoinositide-linked receptor and the 5-HT-2 site are identical. The 5-HT-2-mediated phosphoinositide response was then used as a measure of 5-HT-2 receptor sensitivity after in viva treatments that alter the availability of 5-HT. Chronic treatment with the 5-HT-2 antagonist mianserin resulted in a significant decrease (52%) in the density of 5-HT-2 binding sites and a significant decrease (49%) in the maximal phosphoinositide hydrolysis response to 5-HT. Depletion of 5-HT levels with para-chlorophenylalanine or chemical denervation of serotonergic neurons with 5,7-dihydroxytryptamine had no significant effect upon 5-HT-2 receptor density or upon the phosphoinositide response to 5-HT. These data suggest that changes or lack of changes in 5-HT-2 receptor density following in viva manipulations reflect the functional state of the receptor.
Central serotonin (5-HT) receptors are divided into 2 broad subclasses based upon radioligand binding data (Leysen et al., 1982; Peroutka and Snyder, 1979) . The 5-HT-1 site is labeled with 3H-5-HT, whereas the 5-HT-2 site is labeled with the 5-HT antagonists, 3H-spiroperidol and 3H-ketanserin. Recent evidence suggests that the 5-HT-1 site can be further divided into at least 3 subtypes (Pazos et al., 1984; Pedigo et al., 198 1; Yagaloff and Hartig, 1985) . For the most part, the 5-HT-1 site responds predictably to in vivo manipulations that alter 5-HT availability. Chemical denervation induces an increase in the density of 'H-5-HT binding sites in the hippocampus (Nelson et al., 1978; Seeman et al., 1980) , and inhibition of 5-HT inactivation with monoamine oxidase inhibitors (Savage et al., 1980b) , or by chronic reuptake blockade (Dumbrille-Ross and Tang, 1983; Wong and Bymaster, 1981) , reduces the number of 5-HT-1 binding sites. Furthermore, chronic treatment with 5-HT receptor agonists, or antagonists, decreases, or increases, the density of 5-HT-1 binding sites, respectively (Samanin et al., 1980; Savage et al., 1980a) . The 5-HT-2 site, on the other hand, does not respond predictably to in vivo manipulations. It does not develop increased density after denervation (Blackshear et al., 1981; Quik and Azmita, 1983; Seeman et al., 1980) and is not down-regulated after chronic 5-HT reuptake blockade (Dumbrille-Ross and Tang, 1983; Peroutka and Snyder, 1980) . Paradoxically, chronic treatment with putative 5-HT antagonists results in a down-regulation of the 5-HT-2 binding site (Blackshear and Sanders-Bush, 1982; Blackshear et al., 1983) .
It is possible that 5-HT-2 receptor sensitivity does respond predictably to in vivo manipulations and that the observed changes (or lack of changes) in 5-HT-2 receptor density are not accompanied by parallel changes in the responsiveness to 5-HT. Studies of behavioral models of 5-HT-2 activation, although not entirely consistent, lend support to this hypothesis. For instance, chemical denervation of 5-HT neurons has no effect on 5-HT-2 receptor density, but it does induce supersensitivity in the head twitch model of 5-HT-2 receptor activation (Nakamura and Fukushima, 1978; Yamamoto and Ueki, 1981) . Futhermore, there are reports that chronic administration of putative 5-HT-2 antagonists induces supersensitivity in behavioral models of 5-HT-2 activation Mogilnicka and Klimek, 1979; Stoltz et al., 1983) . Other groups have failed to confirm this; instead, they found subsensitivity after chronic antagonists (Blackshear and Sanders-Bush, 1982; Lucki et al., 1985) . Although such behavioral responses are clearly mediated by the 5-HT-2 binding site, nonserotonergic neuronal systems undoubtedly come into play, making interpretation of the behavioral results complicated. For instance, behavioral supersensitivity to a 5-HT-2 agonist could represent the loss of inhibitory input from another system rather than 5-HT-2 receptor supersensitivity. Furthermore, it is conceivable that changes in the density of the 5-HT-2 site, which are usually measured in frontal cortex, do not occur on cells involved in mediating the behavioral responses. For these reasons, it would be advantageous to study a 5-HT-2-mediated response that is closely linked to the receptor. This would allow a direct measurement of the relationship between 5-HT-2 receptor density and 5-HT-2 receptor sensitivity.
One response that could serve this purpose is 5-HT-stimulated phosphoinositide hydrolysis. Phosphoinositide hydrolysis is a multifunctional transmembrane transducing mechanism that results in release of at least 2 second messengers (inositol-1,4,5-trisphosphate and diacylglycerol). These second messengers elicit a number of cellular responses, including neurotransmitter release, lysosomal enzyme release, glycogenolysis, DNA synthesis, photoreception, platelet aggregation, and heterologous receptor desensitization (Berridge, 1984) . Recently, it has been suggested that 5-HT-stimulated phosphoinositide hydrolysis in human platelets (de Chaffoy de Courcelles et al., 1985) , rat aorta (Roth et al., 1984 (Roth et al., , 1985 , and rat cerebral cortex Sanders-Bush, 1984, 1985 
Levels of phosphoinositides
The levels of radioactivity in PIP and PIP2 and the specific radioactivity of PI were determined by established methodologies. Cerebral cortices from male Sprague-Dawley rats were dissected and sliced as described previously (Conn and Sanders-Bush, 1985) . Slices were incubated for 30 min (37°C) in a gently shaking bath in Krebs bicarbonate buffer containing 10 mM glucose (KRBG). Slices were then washed with warm KRBG and 300 ~1 aliquots of gravity-packed slices were added to vials containing 12 &I 3H-inositol in 3.3 ml KRBG and incubated for an additional 3 hr (37°C). Free 'H-inositol was washed away with warm KRBG containing 10 mM myo-inositol and 200 ~1 aliquots of gravitypacked slices were transferred to conical centrifuge tubes and rapidly homogenized using a Brinkman polytron. The lipids were immediately extracted as described by Schacht (198 1) . The lipid extract was divided into 4 fractions and evaporated under a stream of nitrogen while kept on ice.
The method of Yavin and Zutra (1977) was used to separate PI from other phospholipids. This method employs 2-dimensional thin-layer chromatography (TLC) and gives excellent separation of PI from phosphatidylserine compared with other TLC methods. Briefly, fractions were spotted on Brinkman silica gel G plates and developed in the first dimension using chloroform/methanol/40°h methylamine (13:6: 1.5). The plates were dried under warm air and exposed to fumes of HCl to neutralize the methylamine. The plates were then developed in a solvent system consisting of chloroform/acetone/methanol/acetic acid/water (10: 4:2:3:1). The dried plates were sprayed with Enhance (New England Nuclear) and exposed to X-ray film for 2-3 d. Only 1 radioactive spot was visible. This corresponds to PI as determined by TLC of standards run simultaneously. The spot corresponding to PI was scraped into acidwashed test tubes for the determination of phosphate. Phosphate content was determined by the method of Van Dongen et al. (1985) , using KH,PO, as a standard. Two of the 4 fractions were analyzed in this manner and the values were averaged.
Radioactivity in all 3 phosphoinositides was determined in the second pair of fractions. Samples were spotted on silica gel 60 plates (American Scientific) and run in l-dimension using chloroform/methanol/4 N NH,OH as the solvent system (Gonzalez-Sastre and Folch-Pi, 1968) . Standard nonlabeled phosphoinositides were run simultaneously, and the spots were visualized with iodine vapor. The R, values of PI, PIP, and PIP2 were 0.59, 0.34, and 0.12, respectively. Sections, 1 cm, were scraped into counting vials and the radioactivity quantitated by liquid scintillation counting. Only 4 radioactive peaks were found, 3 of which agree with the 3 phosphoinositide standards. The fourth radioactive peak (which represented less than 10% of the radioactivity spotted) had an R, value (0.47), which corresponded with a lyso PI standard.
Radioligand binding
For competition binding studies, the binding of 3H-ketanserin was measured in buffer containing physiological salts as described previously (Conn and Sanders-Bush, 1985) . IC,, values were determined from Hill plots of competition binding data. K, values were calculated by the method of Cheng and Prusoff (1973) . Scatchard analyses of 3H-ketanserin binding were performed as previously described (Conn and Sanders-Bush, 1985) except that physiological salts were omitted.
Phosphoinositide hydrolysis
Measurement of agonist-induced phosphoinositide hydrolysis was as described previously (Conn and Sanders-Bush, 1985) except that 25 ~1 aliquots of gravity-packed slices were labeled for various times in tubes containing l-2 PCi 3H-inositol and 200 ~1 KRBG. Drugs were added directly to these tubes, and subsequent incubations were-in the continuous presence of 'H-inositol. Pargyline ( 10 PM) and LiCl(l0 mM) were routinely added to the incubation medium. Pargyline shifts the 5-HT concentration response curve leftward and eliminates the nonspecific effects of high concentrations of 5-HT (Conn and Sanders-Bush, 1985) . Lithium inhibits the metabolism of inositol phosphate (IP) and allows the direct measurement of 'H-IP released from labeled phosphoinositides (Berridae et al., 1982) . 'H-inositol was stored with a small amount ~ -,
of Dowex-1 anion-exchange resin in the formate form in order to maintain purity. The specific radioactivity of PI increases linearly with increasing labeling incubation time, and the ratio of radioactivity in PIP and in PIP2 relative to PI remains constant (data not shown). Furthermore, the radioactivity present in )H-IP increases linearly with increasing labeling time, but the percentage-response to 5-HT is independent of labeling time (data not shown). Thus, different labeling times (l-3 hr) were used depending on the particular needs of the experiments. For Schild analyses, it was important to have maximum labeling of IP in order to increase the accuracy of EC,, estimates. For this reason, slices were labeled for 3 hr. After lesioning with 5,7-DHT, it was necessary to reduce incubation time to 1 hr in order to preserve the integrity of the tissue. In these samples, 2 PCi of 'H-inositol was added rather than the usual 1 &i. For all other experiments, labeling was for 2 hr.
Schild analyses
Antagonist Kd values at the phosphoinositide-linked receptor were estimated using the method of Arunlakshana and Schild (1959) . Briefly, the concentration response curve of 5-HT was determined in the presence of various concentrations of antagonists. The 5-HT concentrationresponse curves were progressively shifted to the right with increasing concentrations of antagonists. EC,, values of 5-HT were determined at each antagonist concentration, and dose ratio (DR) values were calculated by dividing the EC,, of 5-HT in the absence of antagonist by the EC,, of 5-HT in the presence of antagonist. If the regression analysis of log(DR-1) versus -log antagonist concentration was consistent with a straight line with a slope of unity, this was interpreted as indicative of competitive antagonism (Arunlakshana and Schild, 1959) . In cases where competitive antagonism was found, extrapolation of the regression line to the X-axis gave a value theoretically equal to the negative log of the Mayer and Shoup (1983) was employed using a mobile phase of 6% acetonitrile in buffer, a column temperature of 25°C and a single electrode. N-Methylserotonin was routinely added as an internal standard.
In vivo drug treatments
Male Sprague-Dawley rats were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN) . Three different in vivo manipulations were used to alter 5-HT availability. For each of these treatments, a control group of animals was injected with vehicle only.
Mianserin-treated rats were injected subcutaneously with mianserin (5 mg/kg) daily for 10 consecutive days. Animals were sacrificed 48 hr after the last injection, and cerebral cortices were dissected and used for PCPA-treated animals were injected intraperitoneally with 200 mg/ kg daily for 4 consecutive days. Rats were sacrificed 48 hr after the last injection, and cerebral cortices were dissected and used for measurement of 'H-ketanserin binding, phosphoinositide hydrolysis, or phospholipid levels. Hippocampi were dissected as described by Glowinski and Iversen (1966) for the determination of monoamine levels. The neurotoxin 5,7-DHT was injected intraventricularly according to the method of Janowsky et al. (1982) . Sixty minutes before injection of the neurotoxin, desipramine (25 mp/kg, i.p.) was administered to protect noradrenergic neurons (Bjiirklund et al., 1975) . 5,7-DHT, 150 rg dissolved in 20 ~1 of 0.9% saline containing 0.1% ascorbic acid, was injected into the lateral ventricle over a period of 5 min. Control rats received desipramine and an intraventricular injection of vehicle. Nine to 12 d after surgery, animals were sacrificed, and cerebral cortices were dissected and used for 3H-ketanserin binding or for the measurement of phosphoinositide hydrolysis. The levels of monoamines in hippocampi were determined as an index of the effect of the lesion.
Results

Schild analyses
The 5-HT antagonists-spiperone, ketanserin, pizotifen, miansetin, cinanserin, trazadone, clozapine, and promethazinecaused concentration-dependent rightward shifts of the 5-HT concentration response curves. The Schild regression lines of these data gave slopes close to unity for all antagonists except clozapine (Fig. 1, Table 1 ). The Schild slope of clozapine was 1.5, indicating that this drug may not interact with the phosphoinositide-linked receptor in a simple competitive manner. Thus, a Kd value of clozapine at the phosphoinositide-linked receptor could not be determined.
K, values at the 3H-ketanserin labeled 5-HT-2 binding site were estimated from competition binding data (Table 1) . The rank order of the antagonists' potencies at the phosphoinositidelinked receptor was identical to the rank order for inhibition of binding to the 5-HT-2 site. Furthermore, regression analysis of the Kd values at the phosphoinositide-linked receptor versus K, values at the 5-HT-2 site (Fig. 2) gave a correlation coefficient of 0.98 (p < 0.001). K, values estimated by Schild analyses were generally higher than those determined in radioligand binding assays. Different tissue preparations (slices versus homogenates) were used for the two assays, which may explain the observed differences in potencies. 
Chronic treatments
Scatchard analyses of 3H-ketanserin binding in cerebral cortices of rats treated chronically with mianserin showed a significant reduction (48% of control) in the density of 5-HT-2 binding sites with no effect upon the K,, value (Table 2) . Two-way analysis of variance (ANOVA) revealed a significant main effect of mianserin treatment (p < 0.001) upon 5-HT-stimulated phosphoinositide hydrolysis in cerebral cortical slices (Fig. 3) . Mianserin treatment caused a significant reduction (5 1% of control) in the maximal phosphoinositide response elicited by 5-HT, with no change in the EC,, value. The EC,, values of 5-HT in control and treated rats were 1.3 f 0.4 and 2.4 f 1.0 MM, respectively. The specific radioactivity of PI and the relative radioactivity in the polyphosphoinositides were not altered by the treatment (Table 2) .
Chronic administration of PCPA had no significant effect upon the density of 5-HT-2 binding sites or upon the affinity of 3H-ketanserin at the 5-HT-2 binding site (Table 2) this treatment did not change the cerebral cortical phosphoinositide response to 5-HT (Fig. 4) or the radioactivity present in the phosphoinositides (Table 2) . PCPA caused a greater than 97% reduction in the levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) with no statistically significant effect upon levels of norepinephrine (data not shown).
Chemical denervation with 5,7-DHT resulted in a 90% depletion of 5-HT and 5-HIAA with no significant effect upon NE levels (data not shown). Treatment with 5,7-DHT did not change the density of 5-HT-2 binding sites or the Kd value of 3H-ketanserin (Table 2) . Furthermore, this treatment had no significant effect upon the maximum phosphoinositide response to 5-HT (Fig. 5) . The 5-HT concentration response curve was slightly shifted to the left in lesioned animals but 2-way ANOVA revealed that the main effect of lesions was not statistically significant (p = 0.09). The EC,, value of 5-HT was less in 6 of the 7 lesioned rats compared with controls analyzed simultaneously: mean EC,, values in control and lesioned rats of 0.6 1 f 0.1 and 0.38 f 0.1, respectively. However, the difference in EC,, values did not reach statistical significance (I, = 0.1). 5,7-DHT treatment had no effect upon the incorporation of 3H-inositol into any of the phosphoinositides (Table 2) . 
Discussion
The present results confirm previous reports that 5-HT-2 antagonists inhibit 5-HT-stimulated phosphoinositide hydrolysis Sanders-Bush, 1984, 1985; de Chaffoy de Courcelles et al., 1985; Kendall and Nahorski, 1985; Roth et al., 1984) and extend those findings by showing that a significant correlation exists between Schild analysis determined Kd values at the cerebral cortical phosphoinositide-linked receptor and K, values at the 5-HT-2 binding site. The phosphoinositide response to some agonists does not reflect a direct coupling of a receptor to phosphoinositide hydrolysis but is secondary to agonist-induced increases in neurotransmitter release (Bone and Michell, 1985) or arachidonate metabolism (Rittenhouse, 1984; Watson et al., 1985) . We have previously shown that 5-HT's effect on phosphoinositide hydrolysis in cerebral cortical slices apparently is not secondary to either of these indirect mechanisms (Conn and Sanders-Bush, 1986a) . Taken together, these data provide strong evidence that phosphoinositide hydrolysis is the transducing mechanism linked to the 5-HT-2 receptor. 5-HT stimulates phosphoinositide hydrolysis in rat choroid plexus with a pharmacology similar to that of the 5-HT-lc binding site (Conn et al., 1986) . This recently described binding site is present in high density in the choroid plexus (Pazos et al., 1984; Yagaloff and Hartig, 1985) . The 5-HT-lc-mediated phosphoinositide response apparently is not mediated by 5-HTstimulated arachidonate metabolism or neurotransmitter release (Conn and Sanders-Bush, 1986b) . Thus, at least 2 5-HT receptor subtypes appear to utilize phosphoinositide hydrolysis for signal transduction. The properties of the phosphoinositide response to activation of these 2 receptors has recently been reviewed (Sanders-Bush and Conn. 1986a, b) .
Given the evidence that the 5-HT-2 site is directly coupled to phosphoinositide hydrolysis, we employed this response as a measure of 5-HT-2 receptor activation in order to determine the effect of in viva manipulations of 5-HT availability upon 5-HT-2 receptor responsiveness. Consistent with previous reports (Blackshear and Sanders-Bush, 1982; Blackshear et al., 1983) , chronic administration of the 5-HT-2 antagonist, mianserin, resulted in a marked decrease in the density of 5-HT-2 binding sites (48% of control), with no effect upon the Kd of 3H-ketanserin. This was accompanied by a corresponding decrease in the maximum phosphoinositide response to 5-HT (52% of control), with no effect upon the EC,, value of 5-HT. The excellent agreement between the percentage decrease in the density of the 5-HT-2 binding site and the maximum phosphoinositide response to 5-HT further supports the hypothesis that the 5-HT-2 site is linked to phosphoinositide hydrolysis. Furthermore, this finding demonstrates that chronic mianserin-induced down-regulation of the 5-HT-2 site is accompanied by 5-HT-2 receptor subsensitivity. It is unclear why 5-HT-2 antagonists induce this paradoxical desensitization, and it remains a challenge to determine the mechanism by which mianserin and other 5-HT-2 antagonists induce such changes.
Also consistent with previous reports is the finding that chemical lesioning of 5-HT neurons with 5,7-DHT or the administration of PCPA results in profound, selective depletion of 5-HT and its metabolite but has no effect upon the density of the 5-HT-2 binding site (Blackshear et al., 198 1; Quik and Azmita, 1983; Seeman et al., 1980) . Destruction of noradrenergic neurons has a similar lack of effect upon a,-adrenergic receptor density. However, noradrenergic denervation induces a supersensitive q-mediated phosphoinositide response (Akhtar and Abdel-Latif, 1986; Janowsky et al., 1984; Kendall et al., 1985; Zatz, 1985) . This suggests that the cr,-receptor is regulated by alterations in receptor-effecter coupling rather than alterations in receptor density. Given the possibility that the 5-HT-2 receptor system is regulated in a similar manner, it was of interest to determine the effect of serotonergic denervation or depletion upon 5-HT-2-mediated phosphoinositide hydrolysis. The current results show that 5-HT-stimulated phosphoinositide hydrolysis was unchanged following these treatments, suggesting that regulation of the 5-HT-2 receptor system is not analogous to regulation of the 01, -adrenergic receptor.
Lesioning of 5-HT neurons with 5,7-DHT does result in supersensitive 5-HT-2-mediated behavioral responses (Nakamura and Fukushima, 1978; Yamamoto and Ueki, 198 l) , and some reports indicate that chronic administration of 5-HT-2 antagonists does the same Mogilnicka and Klimek, 1979; Stolz et al., 1982) . Evidently, this supersensitivity reflects a change that occurs distal to the receptor/effecter complex, since neither the binding nor the transducing mechanism is altered. An example of such regulation exists in 1321Nl astrocytoma cells in which sensitivity to muscarinic agonists is regulated by changes in sensitivity of the cell to inositol trisphosphate, a second messenger released upon stimulation of phosphoinositide hydrolysis. This is not accompanied by alterations in muscarinic binding properties or in carbachol-induced phosphoinositide hydrolysis (Masters et al., 1985) . Another possible mechanism of regulation, which exists in the CNS, is an alteration of the activity of a neuronal system that is antagonistic to the serotonergic systems involved in these 5-HT-2-mediated behavioral responses. If activity of such a system is decreased following 5-HT denervation, it could result in supersensitive behavioral responses to 5-HT.
Since the assay system used in this study measures the release of radioactivity in IP as an index of phosphoinositide hydrolysis, it is conceivable that in vivo manipulations could alter the specific radioactivity of the phosphoinositide precursors of IP and thus compromise interpretation of the results. However, none of the in vivo drug treatments altered the specific radioactivity of PI or the relative radioactivity in PIP or PIP2. These results suggest that the radioactivity present in IP has the same relation to IP mass in treated and in untreated rats. However, these data do not rule out the possibility that the manipulations specifically alter small phosphoinositide pools that are directly accessible to the 5-HT-2 receptor.
In conclusion, the present study provides further evidence that phosphoinositide hydrolysis is the transducing system of the 5-HT-2 receptor. Furthermore, this study shows that antagonist-induced 5-HT-2 receptor down-regulation is accompanied by S-HT-2 receptor subsensitivity and that denervation has no effect upon the 5-HT-2 binding site or upon 5-HT-2 receptor sensitivity.
Future studies should be aimed at determining the mechanism of development of supersensitivity to 5-HT-2 activation seen in behavioral models of 5-HT-2 activity.
